RT Journal Article
SR Electronic
T1 Role of the complement system in Long COVID
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.14.24304224
DO 10.1101/2024.03.14.24304224
A1 Farztdinov, Vadim
A1 Zühlke, Boris
A1 Sotzny, Franziska
A1 Steinbeis, Fridolin
A1 Seifert, Martina
A1 Kedor, Claudia
A1 Wittke, Kirsten
A1 Tober-Lau, Pinkus
A1 Zoller, Thomas
A1 Textoris-Taube, Kathrin
A1 Ludwig, Daniela
A1 Dierks, Clemens
A1 Bierbaum, Dominik
A1 Sander, Leif Erik
A1 Hanitsch, Leif G
A1 Witzenrath, Martin
A1 Kurth, Florian
A1 Mülleder, Michael
A1 Scheibenbogen, Carmen
A1 Ralser, Markus
YR 2024
UL http://medrxiv.org/content/early/2024/03/18/2024.03.14.24304224.abstract
AB Long COVID, or Post-Acute COVID Syndrome (PACS), may develop following SARS-CoV-2 infection, posing a substantial burden to society. Recently, PACS has been linked to a persistent activation of the complement system (CS), offering hope for both a diagnostic tool and targeted therapy. However, our findings indicate that, after adjusting proteomics data for age, body mass index and sex imbalances, the evidence of complement system activation disappears. Furthermore, proteomic analysis of two orthogonal cohorts—one addressing PACS following severe acute phase and another after a mild acute phase—fails to support the notion of persistent CS activation. Instead, we identify a proteomic signature indicative of either ongoing infections or sustained immune activation similar to that observed in acute COVID-19, particularly within the mild-PACS cohort.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Ministry of Education and Research (BMBF), as part of the National Research Initiative - Mass Spectrometry in Systems Medicine - (MSCoreSys), under grant agreement number 01EP2201 (to MR) and 16LW0239K (to MM), under Grant 01EP2201 (to CS) as well as the. Weidenhammer-Zoebele Foundation, and the Berlin University Alliance (BUA Link Lab, 501_Massenspektrometrie, 501_Linklab).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The PA-COVID-19 study is a prospective observational study registered with German clinical trials registry (DRKS 00021688) aiming to provide a platform for clinical characterisation of acute and post-acute COVID-19. The study was approved by the ethics committee of Charite - Universitaetsmedizin Berlin (EA2/066/20) and conducted in accordance with the declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.